Eledon Pharmaceuticals (ELDN) Enterprise Value (2014 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Enterprise Value data on file, last reported at -$111.1 million in Q1 2026.

• Quarterly Enterprise Value rose 53.96% year-over-year to -$111.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$111.1 million (up 53.96% YoY) and the FY2025 annual result came in at -$133.3 million, up 4.88% from the prior year.
• Enterprise Value rose to -$111.1 million in Q1 2026, from -$133.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$9.2 million in Q1 2022 to a low of -$241.3 million in Q1 2025.
• A 5-year average of -$82.4 million and a median of -$71.4 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value soared 90.9% — and 2023, when it tumbled 675.85%.
• Tracing ELDN's Enterprise Value over 5 years: stood at -$56.4 million in 2022, then advanced by 9.41% to -$51.1 million in 2023, then tumbled by 174.31% to -$140.2 million in 2024, then grew by 4.88% to -$133.3 million in 2025, then increased by 16.68% to -$111.1 million in 2026.
• The last three Enterprise Value figures came in at -$111.1 million (Q1 2026), -$133.3 million (Q4 2025), and -$93.4 million (Q3 2025), per Business Quant data.